Mistakes are rarely rewarded. Intuitively, one would imagine that a shoddy typist at an office who keeps generating typos would either quickly lose their job, or at least be overlooked for promotion. The idea that this person ...
Evolution
Mar 26, 2020
0
171
How bacteria live—whether as independent cells or in a communal biofilm—determines how they evolve antibiotic resistance, which could lead to more personalized approaches to antimicrobial therapy and infection control.
Cell & Microbiology
Oct 23, 2019
0
100
Pharmaceuticals commonly found in the environment are disrupting streams, with unknown impacts on aquatic life and water quality. So reports a new Ecological Applications paper, which highlights the ecological cost of pharmaceutical ...
Environment
Apr 1, 2013
2
0
Over the past 20 years, concentrations of pharmaceuticals have increased in freshwater sources all over the world, as research by environmental experts at Radboud University has revealed. Levels of the antibiotic ciprofloxacin ...
Environment
Feb 22, 2019
0
1587
Antibiotics have saved many lives by rescuing patients with bacterial or fungal infections, but these valuable drugs also have a dark side. As with most clinical drugs, many antibiotics can also have undesired effects on ...
Cell & Microbiology
Oct 1, 2018
0
219
The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist ...
Biochemistry
Jun 23, 2010
0
0
The team led by Professor Dr. Klaus Kümmerer has now succeeded in developing antibiotics of this class of substances that become innocuous in the environment by natural degradation.
Other
Nov 30, 2017
0
5
Ciprofloxacin (INN) is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. It is a second-generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops synthesis of DNA and of protein.
Ciprofloxacin was first patented in 1983 by Bayer A.G. and subsequently approved by the U.S. Food and Drug Administration (FDA) in 1987. Ciprofloxacin has 12 FDA-approved human uses and other veterinary uses, but it is often used for unapproved uses (off-label). Ciprofloxacin interacts with other drugs, herbal and natural supplements, and thyroid medications.
As of 2011 the FDA has added two black box warnings for this drug in reference to spontaneous tendon ruptures and the fact that ciprofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Such an adverse reaction is a potentially life-threatening event and may require ventilatory support.
This text uses material from Wikipedia, licensed under CC BY-SA
